Ac immune reports first quarter 2025 financial results and provides a corporate update

Ac immune reports first quarter 2025 financial results and provides a corporate update continuing to advance clinical active immunotherapy portfolio for precision prevention of neurodegenerative diseases positive immunogenicity and good safety in interim results for wholly owned anti-alpha-synuclein (a-syn) active immunotherapy aci-7104.056 in phase 2 trial in parkinson's disease (pd) additional aci-7104.056 phase 2 interim results (pharmacodynamics and biomarkers) expected in q2 2025 presentations at international conference on alzheimer's and parkinson's disease (ad/pd™ 2025) highlight leadership in active immunotherapy and promising data on early-stage assets cash resources of chf 145.7 million as of march 31, 2025 provide funding into q1 2027 before any potential milestones lausanne, switzerland, april 30, 2025 -- ac immune sa (nasdaq: aciu), a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, today reported results for the quarter ended march 31, 2025, and provided a corporate update. dr. andrea pfeifer, ceo of ac immune sa, commented: “ac immune's portfolio of active immunotherapies for precision prevention of neurodegeneration continues to advance in clinical development.
ACIU Ratings Summary
ACIU Quant Ranking